Defence Therapeutics Statistics

Total Valuation

Defence Therapeutics has a market cap or net worth of CAD 24.49 million. The enterprise value is 26.20 million.

Market Cap	24.49M
Enterprise Value	26.20M

Important Dates

The next estimated earnings date is Friday, February 21, 2025.

Earnings Date	Feb 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Defence Therapeutics has 47.09 million shares outstanding. The number of shares has increased by 8.82% in one year.

Current Share Class	n/a
Shares Outstanding	47.09M
Shares Change (YoY)	+8.82%
Shares Change (QoQ)	+0.07%
Owned by Insiders (%)	5.11%
Owned by Institutions (%)	n/a
Float	44.68M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.26
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-8.80

Financial Position

The company has a current ratio of 0.04

Current Ratio	0.04
Quick Ratio	0.04
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.62
Interest Coverage	-27.13

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-690.73%
Return on Capital (ROIC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -79.85% in the last 52 weeks. The beta is 1.45, so Defence Therapeutics's price volatility has been higher than the market average.

Beta (5Y)	1.45
52-Week Price Change	-79.85%
50-Day Moving Average	0.57
200-Day Moving Average	1.00
Relative Strength Index (RSI)	40.71
Average Volume (20 Days)	17,412

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-11.12M
Pretax Income	-11.60M
Net Income	-11.60M
EBITDA	-11.05M
EBIT	-11.12M
Earnings Per Share (EPS)	-0.26

Full Income Statement

Balance Sheet

The company has 131,198 in cash and 1.84 million in debt, giving a net cash position of -1.71 million or -0.04 per share.

Cash & Cash Equivalents	131,198
Total Debt	1.84M
Net Cash	-1.71M
Net Cash Per Share	-0.04
Equity (Book Value)	-4.12M
Book Value Per Share	-0.09
Working Capital	-4.35M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -2.78 million and capital expenditures -196,739, giving a free cash flow of -2.98 million.

Operating Cash Flow	-2.78M
Capital Expenditures	-196,739
Free Cash Flow	-2.98M
FCF Per Share	-0.06

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Defence Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.82%
Shareholder Yield	-8.82%
Earnings Yield	-49.53%
FCF Yield	-12.15%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a